The total number of records retrieved from this search are 13. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2212	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2213	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result55% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2214	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2215	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2216	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2217	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2218	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2219	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2220	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2221	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2252	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-435(1.0E+6 × 10⁶)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreased by 9 fold after 56 days	Mode of deliveryIntratumoral	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_4429	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration21:1 particle to pfu	In-vitro result98% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4437	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration24:1 particle to pfu	In-vitro result2% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798